GI

Kinarus Receives Grant of Key U.S. Patent for its Lead Therapeutic Candidate

Retrieved on: 
Tuesday, April 26, 2022

Kinarus Receives Grant of Key U.S. Patent for its Lead Therapeutic Candidate

Key Points: 
  • Kinarus Receives Grant of Key U.S. Patent for its Lead Therapeutic Candidate
    Grant of KIN001 composition of matter patent strengthens proprietary position in U.S. until at least 2037
    Basel, Switzerland, April 26, 2022.
  • Kinarus AG ('Kinarus') announced today that the United States Patent and Trademark Office (USPTO) has issued US Patent No.
  • 11285155 entitled "Pharmaceutical Combinations for Treating Cancer" that covers the Kinarus lead therapeutic candidate KIN001.
  • Kinarus' differentiated therapeutic candidate, KIN001, has broad potential in numerous therapeutic areas.

Ironwood Pharmaceuticals to Host First Quarter 2022 Investor Update Call

Retrieved on: 
Thursday, April 21, 2022

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its first quarter 2022 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, May 5, 2022.

Key Points: 
  • Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its first quarter 2022 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, May 5, 2022.
  • The call will be available for replay via telephone starting Thursday, May 5, 2022 at approximately 11:30 a.m. Eastern Time, running through 11:59 p.m. Eastern Time on May 19, 2022.
  • To listen to the replay, dial (800) 770-2030 (U.S. and Canada) or (647) 362-9199 (international) using conference ID number 4671230.
  • Ironwood Pharmaceuticals (Nasdaq: IRWD) is a leading gastrointestinal (GI) healthcare company on a mission to advance the treatment of GI diseases and redefine the standard of care for GI patients.

Inhibikase Therapeutics to Participate at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference

Retrieved on: 
Thursday, April 21, 2022

An archived replay of the webcast will be available for approximately 30 days.

Key Points: 
  • An archived replay of the webcast will be available for approximately 30 days.
  • In addition, the Company recently hosted a virtual Key Opinion Leader investor event on April 20, 2022.
  • Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders.
  • Inhibikase is headquartered in Atlanta, Georgia with offices in Boston, Massachusetts.

Coding for Minimally Invasive Endoscopic Treatments Are Now Available

Retrieved on: 
Monday, April 18, 2022

CENTER VALLEY, Pa., April 18, 2022 /PRNewswire/ -- Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, today announced its support of a new reimbursement from the Centers for Medicare and Medicaid Services that is expected to improve patient access to Endoscopic Submucosal Dissection (ESD) and for per-oral endoscopic myotomy (POEM). Both are minimally invasive procedures performed endoluminally as an alternative to open or laparoscopic surgery.

Key Points: 
  • Both are minimally invasive procedures performed endoluminally as an alternative to open or laparoscopic surgery.
  • Effective Jan. 1, 2022, a new level 1 CPT code is available for 43497, lower esophageal myotomy transoral, i.e.
  • Compared to Endoscopic Mucosal Resection (EMR), ESD allows for the complete en bloc removal rather than piecemeal resection of large tumors greater than 2 cm.
  • "These decisions also present potential to raise patient and HCP awareness about treatment options that are available.

SonoScape receives FDA 510(k) clearance for HD-550 Endoscopy system

Retrieved on: 
Friday, April 15, 2022

Paired with a 4-LED light source, which supports 1080P high definition, the HD-550 endoscopy system enables multi-spectrum and multi-mode.

Key Points: 
  • Paired with a 4-LED light source, which supports 1080P high definition, the HD-550 endoscopy system enables multi-spectrum and multi-mode.
  • Included in the clearance are the 550 series videoscopes, whose maneuverability has been endorsed by top endoscopists around the world.
  • Steven He, Sales Director of SonoScape Endoscopy commented, "This FDA clearance opens up opportunities in one of the world's biggest endoscopy markets, indeed is a powerful boost of our brand recognition, and a tremendously important phase of business development in SonoScape's 20 years' history".
  • Founded in 2002 in Shenzhen China, SonoScape has committed itself to "Caring for Life through Innovation" by providing ultrasound and endoscopy solutions.

SonoScape receives FDA 510(k) clearance for HD-550 Endoscopy system

Retrieved on: 
Friday, April 15, 2022

Paired with a 4-LED light source, which supports 1080P high definition, the HD-550 endoscopy system enables multi-spectrum and multi-mode.

Key Points: 
  • Paired with a 4-LED light source, which supports 1080P high definition, the HD-550 endoscopy system enables multi-spectrum and multi-mode.
  • The HD-550 endoscopy system has been available outside of the USA since 2019.
  • Steven He, Sales Director of SonoScape Endoscopy commented, "This FDA clearance opens up opportunities in one of the world's biggest endoscopy markets, indeed is a powerful boost of our brand recognition, and a tremendously important phase of business development in SonoScape's 20 years' history".
  • Founded in 2002 in Shenzhen China, SonoScape has committed itself to "Caring for Life through Innovation" by providing ultrasound and endoscopy solutions.

Expanded Dyad Leadership Model: United Digestive Announces Dr. Neal C. Patel as President

Retrieved on: 
Thursday, April 14, 2022

ATLANTA, April 14, 2022 /PRNewswire/ -- United Digestive, a leading physician practice management company focused on gastroenterology, today announced Neal C. Patel, MD as its President.

Key Points: 
  • ATLANTA, April 14, 2022 /PRNewswire/ -- United Digestive, a leading physician practice management company focused on gastroenterology, today announced Neal C. Patel, MD as its President.
  • Patel joined Atlanta Gastroenterology Associates, an affiliated practice of United Digestive, in 2014 and has held various leadership roles within the organization ever since.
  • "We are thrilled to welcome Dr. Patel into his new role," said Mark Gilreath, CEO for United Digestive.
  • "His leadership, drive, and commitment are an asset to United Digestive team members, providers, and management.

Seed Expands into Children's Health with Launch of Its First Clinically Studied Pediatric Synbiotic

Retrieved on: 
Wednesday, April 13, 2022

LOS ANGELES, April 13, 2022 /PRNewswire/ -- Seed, the microbiome science company pioneering clinically and scientifically studied next-generation probiotics, today launched its first pediatric innovation, PDS-08™ Pediatric Daily Synbiotic, a clinically studied, two-in-one powdered synbiotic formulated for children and adolescents (ages 3 to 17) with 9 probiotic strains and a fiber-based prebiotic. This launch follows Seed's award-winning flagship synbiotic for adults, DS-01™ Daily Synbiotic, and extends the company's mission to steward the next generation of probiotics to the children's health market.

Key Points: 
  • This launch follows Seed's award-winning flagship synbiotic for adults, DS-01 Daily Synbiotic, and extends the company's mission to steward the next generation of probiotics to the children's health market.
  • PDS-08 is formulated with strains clinically studied in a pediatric population to support digestive health, gut barrier integrity, gut-immune function, and dermatological and respiratory health.
  • Seed Health is a microbiome science company pioneering innovations in probiotics and living medicines to impact human and planetary health.
  • LUCA Biologics , co-founded with Dr. Jacques Ravel, develops living medicines targeting the vaginal microbiome for urogenital and reproductive health.

Seed Expands into Children's Health with Launch of Its First Clinically Studied Pediatric Synbiotic

Retrieved on: 
Wednesday, April 13, 2022

LOS ANGELES, April 13, 2022 /PRNewswire/ -- Seed, the microbiome science company pioneering clinically and scientifically studied next-generation probiotics, today launched its first pediatric innovation, PDS-08™ Pediatric Daily Synbiotic, a clinically studied, two-in-one powdered synbiotic formulated for children and adolescents (ages 3 to 17) with 9 probiotic strains and a fiber-based prebiotic. This launch follows Seed's award-winning flagship synbiotic for adults, DS-01™ Daily Synbiotic, and extends the company's mission to steward the next generation of probiotics to the children's health market.

Key Points: 
  • This launch follows Seed's award-winning flagship synbiotic for adults, DS-01 Daily Synbiotic, and extends the company's mission to steward the next generation of probiotics to the children's health market.
  • PDS-08 is formulated with strains clinically studied in a pediatric population to support digestive health, gut barrier integrity, gut-immune function, and dermatological and respiratory health.
  • Seed Health is a microbiome science company pioneering innovations in probiotics and living medicines to impact human and planetary health.
  • LUCA Biologics , co-founded with Dr. Jacques Ravel, develops living medicines targeting the vaginal microbiome for urogenital and reproductive health.

Progenity to Become Biora Therapeutics as it Completes Transformation

Retrieved on: 
Tuesday, April 12, 2022

As we complete our strategic transformation, we are launching Biora Therapeutics to reflect our mission going forward, which is to reimagine therapeutics and their delivery, said Adi Mohanty, Chief Executive Officer.

Key Points: 
  • As we complete our strategic transformation, we are launching Biora Therapeutics to reflect our mission going forward, which is to reimagine therapeutics and their delivery, said Adi Mohanty, Chief Executive Officer.
  • Progenity expects the brand launch for Biora Therapeutics to coincide with the companys Q1 2022 earnings call in May, and the companys NASDAQ ticker symbol will also change from PROG to BIOR at that time.
  • For updates about Biora Therapeutics, please follow @BioraThera on Twitter.
  • Progenity will become Biora Therapeutics, Inc. during the second quarter of 2022.